Clinical Research
Clinical value of 18F-FDG PET-CT-MRI multimodality imaging in pancreatic cancer
Liu Xuanli, Jiang Shuangshi, Wang Chao, Feng Hongyan, Wang Ke, Tu Ning, Han Fang, Bu Lihong
Published 2023-09-30
Cite as Chin J Metastatic Cancer, 2023, 06(3): 239-245. DOI: 10.3760/cma.j.cn101548-20230425-00060
Abstract
ObjectiveTo explore the value of 18F-FDG PET-CT-MRI multimodality imaging for diagnostic, staging, and prognostic predictive in pancreatic cancer.
MethodsA retrospective analysis of the clinical and imaging data of 87 patients (53 males and 34 females, age (63.3±10.5) years) who underwent 18F-FDG PET-CT-MRI multimodality imaging for suspected occupying pancreatic lesions was performed at the People's Hospital of Wuhan University from March 2018 to September 2022. The diagnostic and staging performance of 18F-FDG PET-CT-MRI multimodality imaging (Kappa test) with conventional 18F-FDG PET-CT was analyzed and compared for pancreatic cancer, using histopathological findings as the "gold standard". The univariate and multifactorial analysis of overall survival (OS) was performed in pancreatic cancer patients using Kaplan-Meier and Cox models to assess the relationship between each imaging biomarker of 18F-FDG PET-CT-MRI multimodality imaging technology and OS.
ResultsThe sensitivity, specificity, and accuracy of 18F-FDG PET-CT-MRI in diagnosing pancreatic cancer were 98.65%, 76.92%, and 95.40%, respectively, which were higher than that of 18F-FDG PET-CT and had a high consistency with pathological results (K=0.807). In terms of TNM staging, the accuracy of 18F-FDG PET-CT-MR imaging was 97.30%, 97.30%, and 100% for the diagnosis of T, N, and M staging of pancreatic cancer, respectively, and the consistency test results with pathological staging were 0.960, 0.976 and 1.000, respectively, all of which were better than 18F-FDG PET-CT and had better diagnostic efficacy. Single-factor survival analysis showed that TNM stage (P=0.008), ADCmean (P=0.023), metabolic tumor volume (MTV, P=0.009), and total focal glycolysis (TLG, P=0.002) were factors influencing patients' OS. In multi-factor analysis, TNM stage, ADCmean, and TLG were independent risk factors influencing patients' OS rate (all P<0.05).
Conclusion18F-FDG PET-CT-MRI multimodality imaging significantly enhances the accuracy of pancreatic cancer diagnosis and staging, and prognosis prediction, improves patient survival and quality of life, and ultimately enables more accurate and personalized treatment.
Key words:
Pancreatic cancer; Tomography, positron-emission; Tomography, X-ray computed; Magnetic resonance imaging; Fluorodeoxyglucose
Contributor Information
Liu Xuanli
Department of PET-CT Medical Center, Zhongshan Hospital of Dalian University, Dalian 116001, China
Jiang Shuangshi
Department of PET Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
Wang Chao
Department of PET Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
Feng Hongyan
Department of PET Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
Wang Ke
Department of PET Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
Tu Ning
Department of PET Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
Han Fang
Department of PET-CT Medical Center, Zhongshan Hospital of Dalian University, Dalian 116001, China
Bu Lihong
Department of PET Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
